Werbung
Deutsche Märkte geschlossen

  • Nikkei 225

    38.385,73
    +29,67 (+0,08%)
     

  • Dow Jones 30

    39.908,00
    +349,89 (+0,88%)
     

  • Bitcoin EUR

    60.543,62
    +3.963,24 (+7,00%)
     

  • CMC Crypto 200

    1.392,96
    +125,01 (+9,86%)
     

  • Nasdaq Compositive

    16.742,39
    +231,21 (+1,40%)
     

  • S&P 500

    5.308,15
    +61,47 (+1,17%)
     

10x Genomics (TXG) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

Zacks Equity Research
·Lesedauer: 2 Min.

10x Genomics (TXG) reported $141.01 million in revenue for the quarter ended March 2024, representing a year-over-year increase of 5%. EPS of -$0.50 for the same period compares to -$0.44 a year ago.

The reported revenue compares to the Zacks Consensus Estimate of $142.04 million, representing a surprise of -0.73%. The company delivered an EPS surprise of -8.70%, with the consensus EPS estimate being -$0.46.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

WERBUNG

Here is how 10x Genomics performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

  • Revenues- Consumables: $110.34 million compared to the $113.47 million average estimate based on two analysts. The reported number represents a change of -1.8% year over year.

  • Revenues- Services: $5.22 million versus $4.38 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +91.1% change.

  • Revenues- Instruments: $25.45 million compared to the $24.28 million average estimate based on two analysts. The reported number represents a change of +32.7% year over year.

View all Key Company Metrics for 10x Genomics here>>>

Shares of 10x Genomics have returned -23.4% over the past month versus the Zacks S&P 500 composite's -2.5% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

10x Genomics (TXG) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research